Viridian Therapeutics, Inc. Common Stock
Symbol: VRDN (NASDAQ)
12.95
▲ (1.01%) 0.130
Company Description:
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Key Stats
- Today's Open: $13.156
- Today's High: $13.156
- Today's Low: $12.586
- Today's Volume: 42.68K
- Yesterday Close: $12.82
- Yesterday High: $13.205
- Yesterday Low: $12.5105
- Yesterday Volume: 471.52K
- Last Min Volume: 434
- Last Min High: $12.979
- Last Min Low: $12.951
- Last Min VWAP: $12.9634
Company Profile
- Name: Viridian Therapeutics, Inc. Common Stock
- Website: https://www.viridiantherapeutics.com
- Listed Date: 2014-06-18
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001590750
- SIC Code: 8071
- SIC description: SERVICES-MEDICAL LABORATORIES
- Market Cap: $1.07B
- Round Lot: 100
- Outstanding Shares: 81.59M
- Asset Type: CS
RECENT FILINGS FOR VRDN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-05-20 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-06 | 10-Q | View |
| 2025-05-06 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-11 | SCHEDULE 13G | View |
| 2025-04-09 | 4 | View |
| 2025-04-09 | 3 | View |
| 2025-04-07 | 8-K | View |
| 2025-03-12 | 4 | View |
| 2025-03-12 | 3 | View |
| 2025-03-12 | 4 | View |
| 2025-03-12 | 3 | View |
| 2025-03-10 | 8-K | View |
| 2025-03-04 | 4 | View |
| 2025-03-04 | 4 | View |
| 2025-03-04 | 4 | View |
| 2025-03-04 | 4 | View |
Latest News on VRDN